Evidence map›Paper›PMID 39548430›Full record

ArticleBMC medicine2024

Triglyceride-lowering therapies in hypertriglyceridemia-associated acute pancreatitis in China: a multicentre prospective cohort study.

Jing Zhou, Zuozheng Wang, Qinghong Liu, Longxiang Cao, Enrique de-Madaria, Gabriele Capurso, Christian Stoppe, Dong Wu, Wei Huang, Yingjie Chen and 29 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. PVNJournal of neuroinflammation · 2026
    Article
  8. Review
  9. Article
  10. Article
  11. Hypertriglyceridemic pancreatitis: perspectives from China.Current opinion in gastroenterology · 2025
    Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

39 authors.

Jing Zhou *Department of Critical Care Medicine, Jinling Hospital, Medical School of Nanjing University, Nanjing, China.
Zuozheng Wang *Department of Hepatobiliary Surgery, General Hospital of Ningxia Medical University, Yinchuan, China.
Qinghong Liu *Department of Emergency, GanZhou People's Hospital, Nanchang University, Nanchang, China.
Longxiang CaoDepartment of Critical Care Medicine, Jinling Hospital, Medical School of Nanjing University, Nanjing, China.
Enrique de-MadariaDepartment of Gastroenterology, Dr. Balmis, General University Hospital-ISABIAL, Alicante, Spain.
Gabriele CapursoPancreato-Biliary Endoscopy and Endosonography Division, Clinical Research Centre, Pancreas Translational, and, San Raffaele Scientific Institute IRCCS, Vita Salute San Raffaele University , Milan, Italy.
Christian StoppeDepartment of Anesthesiology, Intensive Care, Emergency and Pain Medicine, University Hospital Würzburg, Würzburg, 97080, Germany.
Dong WuDepartment of Gastroenterology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Wei HuangCentre of Excellence for Pancreatitis, Institute of Integrated Traditional Chinese and Western Medicine, West China-Liverpool Biomedical Research Centre, West China Hospital, Sichuan University, Chengdu, China.
Yingjie ChenDepartment of Critical Care Medicine, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Siyao LiuDepartment of Emergency Medicine, The First Affiliated Hospital of Xiamen University, Xiamen, China.
Donghuang HongDepartment of Critical Care Medicine, Fujian Provincial Hospital, Fuzhou, China.
Yun SunThe First Department of Critical Care Medicine, The Second Affiliated Hospital of Anhui Medical University, Hefei, China.
Zhenguo ZengDepartment of Critical Care Medicine, Medical Centre of Anesthesiology and Pain, The First Affiliated Hospital of Nanchang University, Nanchang, China.
Kaixiu QinDepartment of Emergency Medicine, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Haibin NiDepartment of Emergency Medicine, Jiangsu Provincial Hospital of Integrated Chinese and Western Medicine, Nanjing, China.
Yi SunThe Fourth Department of the Digestive Disease Centre, Suining Central Hospital, Suining, China.
Yue LongDepartment of Critical Care Medicine, Qian Xi Nan People's Hospital, Zunyi Medical University, Zunyi, China.
Feng GuoDepartment of Intensive Care Unit, Sir Run Run Shaw Hospital of Zhejiang University School of Medicine, Hangzhou, China.
Xiaofeng LiuDepartment of Critical Care Medicine, The First Affiliated Hospital of Gannan Medical University, Ganzhou, China.
Xisheng ZhengDepartment of Critical Care Medicine, Nanyang Central Hospital, Nanyang, China.
Guoxiu ZhangDepartment of Emergency Medicine, The First Affiliated Hospital and College of Clinical Medicineof , Henan University of Science and Technology, Luoyang, China.
Xiangcheng ZhangDepartment of ICU, The Affiliated Huaian No. 1, People's Hospital of Nanjing Medical University, Huaian, China.
Kai ZhouDepartment of Emergency, Medical Centre Hospital of Qionglai City, Chengdu, China.
Yizhe ChenDepartment of Critical Care Medicine, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi, China.
Qinghai JiaoDepartment of Critical Care Medicine, The First Hospital of HanDan, Handan, China.
Xinsen ZouDepartment of Critical Care Medicine, Bishan Hospital of Chongqing Medical University, Chongqing, China.
Xiang LuoDepartment of Critical Care Medicine, Longyan First Affiliated Hospital of Fujian Medical University, Longyan, China.
Gang LiDepartment of Critical Care Medicine, Jinling Hospital, Medical School of Nanjing University, Nanjing, China.
Bo YeDepartment of Critical Care Medicine, Jinling Hospital, Medical School of Nanjing University, Nanjing, China.
Chao LiDepartment of Epidemiology and Health Statistics, School of Public Health, Jiaotong University Health Science Centre, Xi'an, China.
Lanting WangDepartment of Critical Care Medicine, Jinling Hospital, Medical School of Nanjing University, Nanjing, China.
Shuai LiDepartment of Critical Care Medicine, Jinling Hospital, Medical School of Nanjing University, Nanjing, China.
John WindsorSurgical and Translational Research Centre, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.
Yuxiu LiuDepartment of Critical Care Medicine, Jinling Hospital, Medical School of Nanjing University, Nanjing, China.
Zhihui TongDepartment of Critical Care Medicine, Jinling Hospital, Medical School of Nanjing University, Nanjing, China.
Weiqin LiDepartment of Critical Care Medicine, Jinling Hospital, Medical School of Nanjing University, Nanjing, China. ctgchina@medbit.cn.
Lu KeDepartment of Critical Care Medicine, Jinling Hospital, Medical School of Nanjing University, Nanjing, China. ctgkelu@nju.edu.cn.ORCID 0000-0001-8093-5073
Chinese Acute Pancreatitis Clinical Trials Group (CAPCTG)

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNo specific triglyceride-lowering therapy is recommended in patients with hypertriglyceridemia-associated acute pancreatitis (HTG-AP), primarily because of the lack of quality evidence. This study aimed to describe practice variations in triglyceride-lowering therapies for early HTG-AP patients and assess whether more rapid triglyceride decline is associated with improving organ failure.

methodsThis is a multicentre, prospective cohort study recruiting HTG-AP patients with elevated plasma triglyceride (> 11.3 mmol/L) admitted within 72 h from the onset of symptoms. Patients were dichotomised on study day 3 into either target reaching (plasma triglyceride ≤ 5.65 mmol/L) or not. The primary outcome was organ failure-free days (OFFD) to 14 days of enrolment. The association between target-reaching and OFFD was modelled. Additionally, the slope in plasma triglyceride over the first three days in response to treatment was calculated, and its association with OFFD was assessed as a sensitivity analysis.

resultsAmong the 300 enrolled patients, 211 underwent exclusive medical treatment, and 89 underwent various blood purification therapies. Triglyceride levels were available in 230 patients on study day 3, among whom 122 (53.0%) had triglyceride levels of ≤ 5.65 mmol/l. The OFFD was not different between these patients and those in whom plasma triglyceride remained > 5.65 mmol/L [median (IQR): 13 (10-14) vs. 14 (10-14), p = 0.46], even after adjustment for potential confounders. For the decline slopes, there was no significant change in OFFD with a steeper decline slope [risk difference, - 0.088, 95% CI, - 0.334 to 0.158, p = 0.48].

conclusionsTriglyceride-lowering therapies vary greatly across centres. More rapid triglyceride decline was not associated with improving incidence and duration of organ failure.

Indexed as

HypertriglyceridemiaPancreatitisTriglyceridesAdultAgedChinaFemaleHumansHypolipidemic AgentsMaleMiddle AgedProspective StudiesTreatment OutcomeHypolipidemic AgentsTriglyceridesAcute pancreatitisBlood purificationHypertriglyceridemiaOrgan failureTriglyceride

Identifiers

PMID39548430
PMCPMC11566486

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.